Literature DB >> 33600861

Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-κB signaling, oxidative stress and inflammation.

Nabila M E Hassan1, Eman Said1, George S G Shehatou2.   

Abstract

The current work explored the influences of nifuroxazide, an in vivo inhibitor of signal transducer and activator of transcription-3 (STAT-3) activation, on tubulointerstitial fibrosis in rats with obstructive nephropathy using unilateral ureteral obstruction (UUO) model. Thirty-two male Sprague Dawley rats were assigned into 4 groups (n = 8/group) at random. Sham and UUO groups were orally administered 0.5% carboxymethyl cellulose (CMC) (2.5 mL/kg/day), while Sham-NIF and UUO-NIF groups were treated with 20 mg/kg/day of NIF (suspended in 0.5% CMC, orally). NIF or vehicle treatments were started 2 weeks after surgery and continued for further 2 weeks. NIF treatment ameliorated kidney function in UUO rats, where it restored serum creatinine, blood urea, serum uric acid and urinary protein and albumin to near-normal levels. NIF also markedly reduced histopathological changes in tubules and glomeruli and attenuated interstitial fibrosis in UUO-ligated kidneys. Mechanistically, NIF markedly attenuated renal immunoexpression of E-cadherin and α-smooth muscle actin (α-SMA), diminished renal oxidative stress (↓ malondialdehyde (MDA) levels and ↑ superoxide dismutase (SOD) activity), lessened renal protein expression of phosphorylated-STAT3 (p-STAT-3), phosphorylated-Src (p-Src) kinase, the Abelson tyrosine kinase (c-Abl) and phosphorylated nuclear factor-kappaB p65 (pNF-κB p65), decreased renal cytokine levels of transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and monocyte chemoattractant protein-1 (MCP-1) and reduced number of cluster of differentiation 68 (CD68) immunolabeled macrophages in UUO renal tissues, compared to levels in untreated UUO kidneys. Taken together, NIF treatment suppressed interstitial fibrosis in UUO renal tissues, probably via inhibiting STAT-3/NF-κB signaling and attenuating renal oxidative stress and inflammation.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD68; Nifuroxazide; STAT-3; TGF-β1; TNF-α; Tubulointerstitial fibrosis; UUO; pNF-κB p65; α-SMA

Mesh:

Substances:

Year:  2021        PMID: 33600861     DOI: 10.1016/j.lfs.2021.119241

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Signaling pathways of chronic kidney diseases, implications for therapeutics.

Authors:  Qian Yuan; Ben Tang; Chun Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

2.  Roles of SIRT6 in kidney disease: a novel therapeutic target.

Authors:  Xueyan Yang; Jun Feng; Wei Liang; Zijing Zhu; Zhaowei Chen; Jijia Hu; Dingping Yang; Guohua Ding
Journal:  Cell Mol Life Sci       Date:  2021-12-24       Impact factor: 9.261

3.  NSC828779 Alleviates Renal Tubulointerstitial Lesions Involving Interleukin-36 Signaling in Mice.

Authors:  Shin-Ruen Yang; Szu-Chun Hung; Lichieh Julie Chu; Kuo-Feng Hua; Chyou-Wei Wei; I-Lin Tsai; Chih-Chin Kao; Chih-Chien Sung; Pauling Chu; Chung-Yao Wu; Ann Chen; Alexander T H Wu; Feng-Cheng Liu; Hsu-Shan Huang; Shuk-Man Ka
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

4.  The Protective Effect of Ursolic Acid on Unilateral Ureteral Obstruction in Rats by Activating the Nrf2/HO-1 Antioxidant Signaling Pathway.

Authors:  Jun Pei; Moudong Wu; Shuyu Cai; Jinpu Peng; Xiong Zhan; Dan Wang; Wei Wang; Nini An
Journal:  Comput Intell Neurosci       Date:  2022-08-25

Review 5.  Targeting Canonical and Non-Canonical STAT Signaling Pathways in Renal Diseases.

Authors:  Lili Gai; Yuting Zhu; Chun Zhang; Xianfang Meng
Journal:  Cells       Date:  2021-06-27       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.